David Hallal - Net Worth and Insider Trading

David Hallal Net Worth

The estimated net worth of David Hallal is at least $47 Million dollars as of 2024-11-10. David Hallal is the CEO of Alexion Pharmaceuticals Inc and owns about 189,266 shares of Alexion Pharmaceuticals Inc (ALXN) stock worth over $35 Million. David Hallal is the Director, 10% Owner of AlloVir Inc and owns about 19,607,546 shares of AlloVir Inc (ALVR) stock worth over $12 Million. David Hallal is also the Director of ITeos Therapeutics Inc and owns about 0 shares of ITeos Therapeutics Inc (ITOS) stock worth over $0. Details can be seen in David Hallal's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Hallal has not made any transactions after 2022-10-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of David Hallal

To

David Hallal Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David Hallal owns 5 companies in total, including AlloVir Inc (ALVR) , ITeos Therapeutics Inc (ITOS) , and Scholar Rock Holding Corp (SRRK) among others .

Click here to see the complete history of David Hallal’s form 4 insider trades.

Insider Ownership Summary of David Hallal

Ticker Comapny Transaction Date Type of Owner
ALVR AlloVir Inc 2022-10-19 director & 10 percent owner & Chief Executive Officer
ITOS ITeos Therapeutics Inc 2022-06-09 director
SRRK Scholar Rock Holding Corp 2018-05-23 director
LIMIT LIMIT 2016-08-08 director & CEO
LIMIT LIMIT 2021-06-17 director

David Hallal Latest Holdings Summary

David Hallal currently owns a total of 3 stocks. Among these stocks, David Hallal owns 189,266 shares of Alexion Pharmaceuticals Inc (ALXN) as of August 8, 2016, with a value of $35 Million and a weighting of 74%. David Hallal owns 19,607,546 shares of AlloVir Inc (ALVR) as of October 19, 2022, with a value of $12 Million and a weighting of 26%. David Hallal also owns 0 shares of ITeos Therapeutics Inc (ITOS) as of June 9, 2022, with a value of $0 and a weighting of 0%.

Latest Holdings of David Hallal

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALXN Alexion Pharmaceuticals Inc 2016-08-08 189,266 182.50 34,541,045
ALVR AlloVir Inc 2022-10-19 19,607,546 0.62 12,137,071
ITOS ITeos Therapeutics Inc 2022-06-09 0 9.27 0

Holding Weightings of David Hallal


David Hallal Form 4 Trading Tracker

According to the SEC Form 4 filings, David Hallal has made a total of 0 transactions in Alexion Pharmaceuticals Inc (ALXN) over the past 5 years. The most-recent trade in Alexion Pharmaceuticals Inc is the sale of 332 shares on August 8, 2016, which brought David Hallal around $45,531.

According to the SEC Form 4 filings, David Hallal has made a total of 7 transactions in AlloVir Inc (ALVR) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in AlloVir Inc is the sale of 600,000 shares on October 19, 2022, which brought David Hallal around $5 Million.

According to the SEC Form 4 filings, David Hallal has made a total of 2 transactions in ITeos Therapeutics Inc (ITOS) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in ITeos Therapeutics Inc is the sale of 29,615 shares on June 9, 2022, which brought David Hallal around $597,335.

Insider Trading History of David Hallal

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David Hallal Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

David Hallal Ownership Network

Ownership Network List of David Hallal

No Data

Ownership Network Relation of David Hallal

Insider Network Chart

David Hallal Owned Company Details

What does AlloVir Inc do?

Who are the key executives at AlloVir Inc?

David Hallal is the director & 10 percent owner & Chief Executive Officer of AlloVir Inc. Other key executives at AlloVir Inc include director & 10 percent owner & See Remarks Vikas Sinha , General Counsel Edward Miller , and Chief Accounting Officer Brett R Hagen .

AlloVir Inc (ALVR) Insider Trades Summary

Over the past 18 months, David Hallal made no insider transaction in AlloVir Inc (ALVR). Other recent insider transactions involving AlloVir Inc (ALVR) include a net sale of 193,383 shares made by Diana Brainard , a net sale of 65,497 shares made by Brett R Hagen , and a net sale of 82,092 shares made by Vikas Sinha .

In summary, during the past 3 months, insiders sold 50,935 shares of AlloVir Inc (ALVR) in total and bought 0 shares, with a net sale of 50,935 shares. During the past 18 months, 364,999 shares of AlloVir Inc (ALVR) were sold and 2,930,870 shares were bought by its insiders, resulting in a net purchase of 2,565,871 shares.

AlloVir Inc (ALVR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

AlloVir Inc Insider Transactions

No Available Data

David Hallal Mailing Address

Above is the net worth, insider trading, and ownership report for David Hallal. You might contact David Hallal via mailing address: C/o Alexion Pharmaceuticals, Inc, 352 Knotter Drive, Cheshire Ct 06410.